Newsfeeds - Spark Newswire

2 minute read

Earnings

Looking Into Insulet’s Return On Capital Employed

May 26, 9:50 AM

According to Benzinga Pro, during Q1, Insulet (NASDAQ:PODD) earned $27.80 million, a 4.79% increase from the preceding quarter. Insulet's sales decreased to $295.40 million, a 4.0% change since Q4.

PODD

1 minute read

Citigroup Maintains Buy on Insulet, Lowers Price Target to $310

By Benzinga Newsdesk

May 17, 8:10 AM

Citigroup analyst Joanne Wuensch maintains Insulet (NASDAQ:PODD) with a Buy and lowers the price target from $350 to $310.

PODD

2 minute read

Analyst Ratings

Expert Ratings for Insulet

By Benzinga Insights

May 6, 1:02 PM

Within the last quarter, Insulet (NASDAQ:PODD) has observed the following analyst ratings:

PODD

1 minute read

Insulet Q1 Earnings Beats Street View, Says Omnipod 5 Rollout Is ‘Progressing Very Well’

By Vandana Singh

May 6, 9:55 AM

Insulet Corporation (NASDAQ:PODD) posted Q1 profits of $27.8 million, or an EPS of $0.40, beating the consensus of $0.23. Q1…

PODD

1 minute read

Raymond James Maintains Outperform on Insulet, Lowers Price Target to $262

By Benzinga Newsdesk

May 6, 8:43 AM

Raymond James analyst Jayson Bedford maintains Insulet (NASDAQ:PODD) with a Outperform and lowers the price target from $280 to $262.

PODD

30 minute read

Earnings Scheduled For May 5, 2022

By Benzinga Insights

May 5, 4:43 AM

Companies Reporting Before The Bell • Mirum Pharmaceuticals (NASDAQ:MIRM) is expected to report quarterly loss at $1.34 per share on revenue of $8.46 million.

AAOI

1 minute read

Insulet Posts Street-Beating Q4 Earnings, Omnipod Revenues Up ~20%

By Vandana Singh

February 24, 7:41 AM

Insulet Corp's (NASDAQ: PODD)

PODD

4 minute read

The Daily Biotech Pulse: Kodiak Sinks On Adverse Study Outcome, Marinus Flags Delay In Clinical Trial, Mainz Biomed Gains On Positive Regulatory Development

By Shanthi Rexaline

February 23, 9:01 AM

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Kodiak's Wet AMD Treatment KSI-301 Did Not Meet Primary Endpoint In Phase 2b/3 Study

AKBA

15 minute read

Earnings Scheduled For February 23, 2022

By Benzinga Insights

February 23, 4:49 AM

Companies Reporting Before The Bell • Sapiens Intl Corp (NASDAQ:SPNS) is likely to report earnings for its fourth quarter.

AAN

4 minute read

The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow

By Shanthi Rexaline

February 20, 9:06 AM

Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries.

ABCL